We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Osteonecroses in Pediatric Patients With ALL (OPAL)

This study is currently recruiting participants.
Verified March 2014 by Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu, Heinrich-Heine University, Duesseldorf
Sponsor:
ClinicalTrials.gov Identifier:
NCT01619124
First Posted: June 14, 2012
Last Update Posted: March 5, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu, Heinrich-Heine University, Duesseldorf
June 6, 2012
June 14, 2012
March 5, 2014
March 2012
March 2016   (Final data collection date for primary outcome measure)
occurence of early ON stages [ Time Frame: 6 years ]
Calculation of the rate of by MRI detectable (still) asymptomatic patients with early ON stages (I and II) within the patients who develop symptomatic ON in the further course
Same as current
Complete list of historical versions of study NCT01619124 on ClinicalTrials.gov Archive Site
ON incidence [ Time Frame: 6 years ]
Prospective evaluation of incidence of asymptomatic and symptomatic ON in children and adolescents with ALL or LBL
Same as current
Not Provided
Not Provided
 
Osteonecroses in Pediatric Patients With ALL
Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL

Nowadays approximately 80% of children and adolescents with acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) can be cured and become long-term survivors. Avascular osteonecroses (ON) appear as serious side-effect of antileukaemic treatment. Frequently ON are first diagnosed at higher and than irreversible stages (ARCO III, IV). At these advanced stages curative treatment options are not available. Hence ON are associated with considerable morbidity concerning pain and immobility and go along with long-term impairment of quality of life. Therefore early diagnosis of ON in the follow-up of children and young adults with ALL or LBL is a pressing object.

Within the prospective multicentric observational OPAL-trial patients at risk (aged 10 years or older) treated according to the clinical trials ALL-BFM(Berlin-Frankfurt-Muenster Study Group), COALL or NHL (Non Hodgkin Lymphoma)-BFM in Germany should be examined with regard to the development of ON. By using a treatment associated, risk orientated assessment and examination incidence, symptoms and the clinical course of ON are investigated. The validity of MRI screening in the early diagnosis of ON in children and young adults is analysed.

Systematical investigation of patients under antileukaemic treatment is intended to contribute to risk adapted diagnostic strategies and to serve as data base for the subsequent evaluation of preventive and interventional approaches for the treatment of ON. Long-term objective is the reduction of ON-associated morbidity.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
whole blood, serum
Non-Probability Sample
Pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, aged >= 10 and < 18 years
  • Osteonecrosis
  • Acute Lymphoblastic Leukaemia
  • Lymphoblastic Lymphoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
March 2020
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • diagnosis of ALL or LBL
  • age at diagnosis of ALL or LBL ≥ 10 and < 18 years
  • study patient of AIEOP( Associazione Italiana Ematologia ed Oncologia Pediatrica)-BFM, COALL or NHL-BFM in Germany
  • treatment in a hospital participating in OPAL
  • written informed consent

Exclusion Criteria:

  • relapse of ALL or LBL
  • every non evidence based treatment (pharmacological, orthopaedic-conservative, orthopaedic operative) aiming at the prevention of ON during study participation
  • pacemaker, other MRI prohibited devices
  • metal implants in the field of view, other MRI prohibited implants
  • pregnancy
  • claustrophobia
Sexes Eligible for Study: All
10 Years to 18 Years   (Child, Adult)
No
Contact: Michaela Kuhlen, Dr. med. +49 211 81 17687 Michaela.Kuhlen@med.uni-duesseldorf.de
Germany
 
 
NCT01619124
DKS 2011.11
No
Not Provided
Not Provided
Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu, Heinrich-Heine University, Duesseldorf
Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu
Not Provided
Study Chair: Michaela Kuhlen, Dr. med. Heinrich-Heine University, Duesseldorf
Heinrich-Heine University, Duesseldorf
March 2014